Key result
High-intensity statin therapy reduced the cumulative incidence of major cardiovascular events compared to low-moderate-intensity statins in normoglycemic AMI patients, whereas prediabetes and T2DM groups showed comparable outcomes regardless of statin intensity.
Why the study?
Comparative studies regarding long-term clinical outcomes of statin intensity between AMI patients with prediabetes and type 2 diabetes mellitus after successful newer-generation DES implantation are limited.
Does high-intensity statin therapy compared to low-moderate-intensity statin therapy improve clinical outcomes in acute myocardial infarction patients with prediabetes or T2DM after newer-generation DES implantation?
Observational (n=11,612)
Yes
Does high-intensity statin therapy compared to low-moderate-intensity statin therapy improve clinical outcomes in acute myocardial infarction patients with prediabetes or T2DM after newer-generation DES implantation?
High-intensity statin therapy provides greater cardiovascular benefit than low-moderate-intensity therapy in AMI patients with normoglycemia, but this incremental benefit is attenuated in those with prediabetes or T2DM.
Answers are grounded in this paper and cite their sources.
Supports high-intensity statins preferentially in normoglycemic AMI patients; extends evidence that glycemic status modifies statin efficacy.
Background: Comparative studies regarding the long-term clinical outcomes of statin intensity between acute myocardial infarction (AMI) patients with prediabetes and those with type 2 diabetes mellitus (T2DM), after successful implantation of newer-generation drug-eluting stents (DES) with statin treatment, are limited. We compared the 2-year clinical outcomes between these patients. Methods: A total of 11612 AMI patients were classified as statin users (n = 9893) and non-users (n = 1719). Thereafter, statin users were further divided into high-intensity (n = 2984) or low-moderate-intensity statin (n = 6909) treatment groups. Those in these two groups were further classified into patients with normoglycemia, prediabetes, and T2DM. The major outcomes were the occurrence of major adverse cardiac events (MACE), defined as all-cause death, recurrent myocardial infarction (Re-MI), or any repeat coronary revascularization. Results: After adjusting for both high-intensity and low-moderate-intensity statin users, the cumulative incidences of MACE ( p = 0.737, p = 0.062, respectively), all-cause death, Re-MI, and any repeat revascularization were similar between the prediabetes and T2DM groups. In the total study population, both high-intensity and low-moderate-intensity statin treatments showed comparable results. However, the beneficial effects of high-intensity compared to low-moderate-intensity statin therapy were more apparent in the normoglycemia group than hyperglycemia group, as it reduced the cumulative incidences of MACE (aHR: 1.903; 95% CI: 1.203-3.010; p = 0.006) and any repeat revascularization (aHR: 3.248; 95% CI: 1.539-6.854; p = 0.002). Conclusions: In this retrospective registry study, prediabetes and T2DM groups showed comparable clinical outcomes, after administering both high-intensity and low-moderate-intensity statin treatments. Trial registration: Retrospectively registered
No takes yet. Share an insight, caveat, or question.
Kim et al. (2020) conducted an observational in Acute Myocardial Infarction (n=11,612). High-intensity statin vs. Low-moderate-intensity statin was evaluated on Major adverse cardiac events (MACE) in the normoglycemia group (aHR 1.903, 95% CI 1.203-3.010, p=0.006). High-intensity statin therapy reduced the cumulative incidence of major cardiovascular events compared to low-moderate-intensity statins in normoglycemic AMI patients, whereas prediabetes and T2DM groups showed comparable outcomes regardless of statin intensity.
Synapse has enriched 10 related papers. Consider them for comparative context: